Insights

Innovative Therapeutics VectorY specializes in cutting-edge gene therapy and vectorized antibody platforms targeting neurodegenerative and muscle diseases, creating opportunities for partnerships with pharmaceutical companies seeking novel treatments for high unmet medical needs.

Strategic Collaborations The company's recent partnerships with Shape Therapeutics for neurodegenerative programs indicate openness to external collaborations, suggesting potential for joint development projects and licensing agreements with biotech firms focusing on CNS disorders.

Expansion Potential With offices in Amsterdam and Boston, VectorY is expanding its geographic reach into the US market, offering opportunities to connect with academic institutions, research centers, and healthcare providers interested in innovative gene therapies.

Strong Funding Backed by $138M in funding and a revenue range of up to $10M, VectorY is well-positioned for scaling operations and advancing clinical trials, presenting opportunities for investors or partners interested in late-stage biotech investments.

Manufacturing Capabilities The company's state-of-the-art GMP manufacturing facilities enable scalable production of viral vectors, which can be attractive for contract manufacturing organizations (CMOs) and biotech firms requiring reliable, high-volume capacity for clinical and commercial supplies.

VectorY Tech Stack

VectorY uses 8 technology products and services including Squarespace, Cart Functionality, Google Fonts API, and more. Explore VectorY's tech stack below.

  • Squarespace
    Content Management System
  • Cart Functionality
    E-commerce
  • Google Fonts API
    Font Scripts
  • Stimulus
    Javascript Frameworks
  • Priority Hints
    Performance
  • HSTS
    Security
  • Google Tag Manager
    Tag Management
  • X-Content-Type-Options
    Web & Portal Technology

Media & News

VectorY's Email Address Formats

VectorY uses at least 1 format(s):
VectorY Email FormatsExamplePercentage
First.Last@vectorytx.comJohn.Doe@vectorytx.com
82%
Last@vectorytx.comDoe@vectorytx.com
8%
First.MiddleLast@vectorytx.comJohn.MichaelDoe@vectorytx.com
7%
First.Middle@vectorytx.comJohn.Michael@vectorytx.com
3%

Frequently Asked Questions

Where is VectorY's headquarters located?

Minus sign iconPlus sign icon
VectorY's main headquarters is located at Amsterdam, North Holland Netherlands. The company has employees across 3 continents, including EuropeNorth AmericaAsia.

What is VectorY's official website and social media links?

Minus sign iconPlus sign icon
VectorY's official website is vectorytx.com and has social profiles on LinkedInCrunchbase.

What is VectorY's SIC code NAICS code?

Minus sign iconPlus sign icon
VectorY's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does VectorY have currently?

Minus sign iconPlus sign icon
As of April 2026, VectorY has approximately 98 employees across 3 continents, including EuropeNorth AmericaAsia. Key team members include Chief Business Officer: J. A.Chief Technology Officer: B. S.Vice President Human Resources: L. B.. Explore VectorY's employee directory with LeadIQ.

What industry does VectorY belong to?

Minus sign iconPlus sign icon
VectorY operates in the Biotechnology Research industry.

What technology does VectorY use?

Minus sign iconPlus sign icon
VectorY's tech stack includes SquarespaceCart FunctionalityGoogle Fonts APIStimulusPriority HintsHSTSGoogle Tag ManagerX-Content-Type-Options.

What is VectorY's email format?

Minus sign iconPlus sign icon
VectorY's email format typically follows the pattern of First.Last@vectorytx.com. Find more VectorY email formats with LeadIQ.

How much funding has VectorY raised to date?

Minus sign iconPlus sign icon
As of April 2026, VectorY has raised $138M in funding. The last funding round occurred on Nov 13, 2023 for $138M.

When was VectorY founded?

Minus sign iconPlus sign icon
VectorY was founded in 2020.

VectorY

Biotechnology ResearchNorth Holland, Netherlands51-200 Employees

VectorY combines the therapeutic potential of antibodies and gene therapy to develop long-lasting therapeutic solutions for large disease areas of high unmet medical need.

By combining state-of-the-art technologies and novel and scientific concepts, VectorY’s mission is to bring innovative therapies to patients worldwide.

Founded in August 2020, and based in the Amsterdam Science Park, VectorY is a fully integrated gene therapy company focused on the development of innovative therapeutics such as vectorized antibodies for both CNS and somatic disorders, with a special focus on muscle diseases.

With R&D and manufacturing facilities in Amsterdam, VectorY develops proprietary & partnered programs based on its novel AAV-based vectorized antibody & gene therapy platform. Product candidates are based on new vector technologies, which will enable the next generation of highly scalable manufacturing processes within VectorY’s own manufacturing facilities. Our manufacturing capabilities will include a state-of-the-art multi-product GMP facility in the Netherlands, with the capability to deliver suspension based AAV viral vector manufacturing of up to 2000L for both clinical and commercial supply.

Section iconCompany Overview

Headquarters
Amsterdam, North Holland Netherlands
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2020
Employees
51-200

Section iconFunding & Financials

  • $138M

    VectorY has raised a total of $138M of funding over 2 rounds. Their latest funding round was raised on Nov 13, 2023 in the amount of $138M.

  • $10M$25M

    VectorY's revenue is estimated to be in the range of $10M$25M

Section iconFunding & Financials

  • $138M

    VectorY has raised a total of $138M of funding over 2 rounds. Their latest funding round was raised on Nov 13, 2023 in the amount of $138M.

  • $10M$25M

    VectorY's revenue is estimated to be in the range of $10M$25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.